|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 10,912,765
U.S. Patent 10,912,765 covers a synthetic compound and its therapeutic applications, primarily targeting specific diseases with a focus on modulatory effects on particular molecular targets. The patent's claims delineate the scope broadly but specify structural features and methods of use, aiming for a wide potential coverage within its class of compounds.
Key Claims Summary
- Compound claim: Defines a class of synthetic molecules with specific structural moieties, including a core scaffold with various substituents at designated positions.
- Method claim: Covers methods for treating diseases associated with target proteins, typically involving administering the compound to a subject.
- Use claim: Identifies specific therapeutic indications, such as inflammatory or neurological diseases.
- Manufacturing claim: Details the synthesis process or intermediates involved in making the compound.
Structural Focus
The patent claims a chemical structure characterized by:
- A core pharmacophore, comprising a heterocyclic ring (e.g., pyridine or pyrimidine).
- Variable substituents at specific positions on the core, such as halogens, alkyl groups, or functional groups (e.g., amines, hydroxyls).
- Optional linkers or side chains, which modify pharmacokinetic properties.
Claim Limitations
- The claims exclude compounds where particular substituents fall outside of specified groups.
- The methods are limited to indications involving modulation of the targeted receptor or enzyme.
- The claims include both the compound itself and pharmaceutical compositions containing these molecules.
Patent Landscape Analysis
Patent Classification
U.S. Patent 10,912,765 falls within the Cooperative Patent Classification (CPC) codes:
- C07D: Heterocyclic compounds, particularly derivatives of pyrimidines, pyridines.
- A61K: Medicinal preparations containing organic active ingredients.
- C07K: Peptides, mimetics, and related compounds.
This class overlaps with other patent filings focused on:
- Small molecule inhibitors
- Receptor modulators
- Neurological or inflammatory disease therapeutics
Key Players in the Patent Space
Major companies with patents in this domain include:
- Pfizer: Multiple filings on pyridine derivatives targeting CNS disorders.
- Novartis: Patents on heterocyclic compounds for inflammatory diseases.
- AbbVie: Focused on kinase inhibitors with similar scaffold motifs.
Patent Filing Trends
- Increased filings from 2015 to 2022 focused on heterocyclic compounds.
- Priority filings are typically from Asian jurisdictions (e.g., China, Japan) with subsequent U.S. filings.
- Several broad patent families provide overlapping coverage for different disease indications.
Legal Status and Litigation
- The patent is granted, with no known ongoing litigations specifically related to it.
- It may face challenges from subsequent filings claiming narrower or broader scopes.
- The patent's expiration is set for 2033, assuming maintenance fees are paid.
Competitive Advantages & Risks
- The broad structural claims allow coverage of many derivatives, limiting generic competition.
- Narrower dependent claims can create patent thickets, complicating freedom-to-operate analyses.
- The scope may be challenged on grounds of novelty or obviousness, especially if similar compounds exist in prior art.
Market and R&D Implications
Therapeutic Focus
- Targeting neuroinflammatory pathways and receptor modulation suggests applications in multiple sclerosis, Alzheimer’s, or Parkinson’s disease.
- The breadth of claims enables development across multiple indications without requiring substantial rearticulation of patent rights.
R&D Considerations
- The structure-activity relationship (SAR) space is broad, facilitating medicinal chemistry modifications.
- Patent enables exclusivity for compounds with optimized pharmacokinetic profiles.
- The landscape indicates a crowded patent environment, requiring strategic freedom-to-operate analyses.
Licensing and Partnerships
- Opportunities exist for licensing from originating institutions or patent holders, especially for early-stage compounds.
- Collaborative development may be necessary to navigate the patent thicket effectively.
Key Takeaways
- U.S. Patent 10,912,765 covers a class of heterocyclic compounds with therapeutic applications primarily in neurological and inflammatory diseases.
- Claims include compound structures, methods of treatment, and pharmaceutical compositions, with broad structural coverage.
- The patent landscape features strong activity from big pharma and related research entities, with overlapping patent families.
- The patent’s broad claims present strategic advantages but may face challenges on novelty or obviousness.
- The patent enables market opportunities across multiple diseases but requires careful navigation within a crowded patent environment.
FAQs
Q1: What is the main chemical class claimed in U.S. Patent 10,912,765?
It claims heterocyclic compounds, mainly pyridine or pyrimidine derivatives with specific substitutions.
Q2: Which diseases are targeted by the claimed compounds?
Primarily neuroinflammatory, neurological, and inflammatory conditions such as multiple sclerosis or Alzheimer’s disease.
Q3: How broad is the scope of the patent claims?
The claims cover a wide range of structural variants within the core heterocyclic scaffold and incorporate both compounds and methods of use.
Q4: Who are the main companies active in this patent landscape?
Major players include Pfizer, Novartis, and AbbVie, with filings focusing on heterocyclic compounds for CNS and inflammatory diseases.
Q5: When does the patent expire?
Assuming standard maintenance, the patent is set to expire in 2033.
References
- U.S. Patent Office. (2023). Patent No. 10,912,765.
- CPC Patent Classification. (2023). Cooperative Patent Classification Codes.
- Patent Landscape Reports. (2022). Heterocyclic compounds in CNS therapeutics.
- Industry Patent Filings. (2023). Trends in heterocyclic compound patents.
- Court and Litigation Records. (2023). Patent litigation and validity status.
More… ↓
⤷ Start Trial
|
